1. Home
  2. QNRX
  3. QNRX News

Latest Quoin Pharmaceuticals Ltd. (QNRX) News on October 8, 2025

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome
QNRX

GlobeNewswire

a month ago

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
QNRX

GlobeNewswire

3 months ago

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
QNRX

GlobeNewswire

3 months ago

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

QNRX

Zacks Small Cap Research

4 months ago

QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further

QNRX

MT Newswires

5 months ago

Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
QNRX

GlobeNewswire

5 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
QNRX

GlobeNewswire

5 months ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

QNRX

MT Newswires

5 months ago

Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
QNRX

GlobeNewswire

5 months ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
QNRX

GlobeNewswire

5 months ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
QNRX

GlobeNewswire

5 months ago

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
QNRX

GlobeNewswire

5 months ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
QNRX

GlobeNewswire

6 months ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

QNRX

MT Newswires

6 months ago

Quoin Pharmaceuticals Changes ADS Ratio to Meet Nasdaq Rule

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
QNRX

GlobeNewswire

6 months ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
QNRX

GlobeNewswire

6 months ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

QNRX

Zacks Small Cap Research

7 months ago

QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
QNRX

GlobeNewswire

7 months ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
QNRX

GlobeNewswire

7 months ago

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease
QNRX

Zacks Small Cap Research

7 months ago

QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
QNRX

GlobeNewswire

7 months ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
QNRX

GlobeNewswire

7 months ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome
QNRX

GlobeNewswire

7 months ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure
QNRX

GlobeNewswire

8 months ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Insider Buyers At Quoin Pharmaceuticals Likely Disappointed With 13% Slide
QNRX

Simply Wall St.

8 months ago

Insider Buyers At Quoin Pharmaceuticals Likely Disappointed With 13% Slide

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
QNRX

GlobeNewswire

9 months ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

QNRX

ACCESS Newswire

9 months ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
QNRX

GlobeNewswire

9 months ago

Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials
QNRX

GlobeNewswire

9 months ago

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
QNRX

GlobeNewswire

9 months ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

QNRX

MT Newswires

9 months ago

Quoin Pharmaceuticals Insider Bought Shares Worth $250,000, According to a Recent SEC Filing

QNRX

MT Newswires

10 months ago

Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
QNRX

GlobeNewswire

10 months ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
QNRX

GlobeNewswire

10 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
QNRX

GlobeNewswire

10 months ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

QNRX

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 12/03/2024

QNRX

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 12/02/2024

QNRX

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/29/2024

QNRX

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/27/2024

QNRX

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/26/2024

QNRX

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 11/25/2024

QNRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/22/2024

QNRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/21/2024

QNRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/20/2024

QNRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/19/2024

QNRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/18/2024

QNRX

Zacks Small Cap Research

a year ago

QNRX: International Sites Participating in QRX003 NS Study, Studying QRX003 for Additional Diseases, in Younger Populations

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

QNRX

Zacks Small Cap Research

a year ago

QNRX: Assessing QRX003 For Multiple Conditions; Opening International Netherton Syndrome Clinical Sites

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Lotto 6/49 - $64 million up for grabs in the next draw!
QNRX

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
QNRX

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
QNRX

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
QNRX

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
QNRX

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
QNRX

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
QNRX

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
QNRX

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals
QNRX

Zacks Small Cap Research

a year ago

QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
QNRX

GlobeNewswire

a year ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript
QNRX

Insider Monkey

2 years ago

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
QNRX

GlobeNewswire

2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
QNRX

GlobeNewswire

2 years ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths
QNRX

Zacks Small Cap Research

2 years ago

QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths

Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
QNRX

GlobeNewswire

2 years ago

Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering

Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
QNRX

GlobeNewswire

2 years ago

Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
QNRX

GlobeNewswire

2 years ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
QNRX

ACCESSWIRE

2 years ago

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mobilicom Announces $2.95 Million Registered Direct Offering
QNRX

GlobeNewswire

2 years ago

Mobilicom Announces $2.95 Million Registered Direct Offering

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
QNRX

GlobeNewswire

2 years ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Mobilicom’s ICE Cybersecurity Software Drone Solutions Purchased by Israel’s Ministry of Defense
QNRX

GlobeNewswire

2 years ago

Mobilicom’s ICE Cybersecurity Software Drone Solutions Purchased by Israel’s Ministry of Defense

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
QNRX

PR Newswire

2 years ago

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

Vista Gold Corp. Announces Strategic Update and 2024 Outlook
QNRX

Business Wire

2 years ago

Vista Gold Corp. Announces Strategic Update and 2024 Outlook

Cineverse Debuts New FAST Channel: Dog Whisperer with Cesar Millan
QNRX

PR Newswire

2 years ago

Cineverse Debuts New FAST Channel: Dog Whisperer with Cesar Millan

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue
QNRX

GlobeNewswire

2 years ago

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue

Exela Technologies Recognized as a Disruptor in Avasant Research Report
QNRX

GlobeNewswire

2 years ago

Exela Technologies Recognized as a Disruptor in Avasant Research Report

LiveOne (Nasdaq: LVO) Provides Update for Its $10M Stock Repurchase Program
QNRX

GlobeNewswire

2 years ago

LiveOne (Nasdaq: LVO) Provides Update for Its $10M Stock Repurchase Program

Mobilicom Secures a new Production-Scale Order for its SkyHopper Pro Lite from IAI for Loitering Drones to be Deployed by Israel Defense Forces
QNRX

GlobeNewswire

2 years ago

Mobilicom Secures a new Production-Scale Order for its SkyHopper Pro Lite from IAI for Loitering Drones to be Deployed by Israel Defense Forces

Safe and Green Development Corporation Announces Update on LOI for Acquisition of Xene Real Estate AI Software
QNRX

GlobeNewswire

2 years ago

Safe and Green Development Corporation Announces Update on LOI for Acquisition of Xene Real Estate AI Software

Five Point Holdings, LLC Announces Early Participation Deadline Results for the Previously Announced Exchange Offer and Consent Solicitation
QNRX

Business Wire

2 years ago

Five Point Holdings, LLC Announces Early Participation Deadline Results for the Previously Announced Exchange Offer and Consent Solicitation

EXCLUSIVE: Foremost Lithium Sets Winter Drilling Agenda At Jean Lake Lithium/Gold Property
QNRX

Benzinga

2 years ago

EXCLUSIVE: Foremost Lithium Sets Winter Drilling Agenda At Jean Lake Lithium/Gold Property

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
QNRX

PR Newswire

2 years ago

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing
QNRX

GlobeNewswire

2 years ago

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing

42West Drives Performance and Global Interest for 'The Boy and the Heron' and 'Godzilla Minus One'
QNRX

ACCESSWIRE

2 years ago

42West Drives Performance and Global Interest for 'The Boy and the Heron' and 'Godzilla Minus One'

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
QNRX

GlobeNewswire

2 years ago

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
QNRX

GlobeNewswire

2 years ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Is Advanced Emissions Solutions (ADES) Stock Outpacing Its Industrial Products Peers This Year?
QNRX

Zacks

2 years ago

Is Advanced Emissions Solutions (ADES) Stock Outpacing Its Industrial Products Peers This Year?

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
QNRX

GlobeNewswire

2 years ago

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
QNRX

PR Newswire

2 years ago

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
QNRX

GlobeNewswire

2 years ago

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

Share on Social Networks: